AF termination rate was lower in the PsAFonset patients and AF/atrial tachycardia recurrence rate after the last procedure was substantially higher (7).
In addition, the difference, for example, in obesity described in the present study by Lim et al. (7) was statistically significant but also not particularly pronounced (body mass index 29 vs. 27 kg/m 2 ).
The striking finding in this subgroup seems to be the diffuse/severe substrate and the poor outcome after ablation (7, 9) . What is the pathophysiological question/clue behind this subgroup with "early persistent" AF? The group is clinically defined from the early/direct appearance of persistent AF in contrast to the "typical" AF history with months, years, or even decades of paroxysmal AF before establishment of persistent AF. But is this clinically defined subgroup also principally different from a pathophysiological aspect? Obviously, we cannot apply the "old conventional wisdom" that "AF begets AF" where the arrhythmia itself is thought to induce structural/fibrotic changes because persistent AF occurs "early" or even "directly from the onset" in this subgroup. Furthermore, arrhythmia-induced fibrosis is also questioned by findings of a very high variability in the amount of fibrosis in AF patients, with some paroxysmal AF patients having massive fibrosis and some persistent AF patients showing mild fibrosis (10).
The specific role of age and risk factors as atrial fibrosis makers has also been questioned in an autopsy study,
where "negligibly" low amounts of fibrofatty tissue were described in atrial specimens from patients with a high CHA 2 DS 2 -VASc (age, sex, congestive heart failure history, hypertension history, stroke/transient ischemic attack/thromboembolism history, vascular disease history, diabetes mellitus) score of 4.3 but no AF (11) . In addition, we recently described a low correlation of risk factors with respect to the fibrotic 
substrate as estimated from electroanatomic voltage mapping in patients with nonparoxysmal AF (6). In the same direction, cardiovascular risk factors were found to be equally distributed in different classes of left atrial fibrosis as described by magnetic resonance imaging studies, and structural atrial remodeling was the same in patients with and without cardiovascular risk factors (12) .
Therefore, if the results in the present study by Lim et al. (7) with obviously diffuse and extensive biatrial substrate in the patients with "early persistent" AF obviously cannot be explained as arrhythmia-induced and also not by the extent of risk factors, then, in our opinion, the fibrotic atrial substrate is a result of a specific disease that we have named/described as "fibrotic atrial cardiomyopathy" (FACM) (Figure 1 ) (13, 14) . FACM is described as a specific disease with different expressions from mild, moderate, to severe atrial fibrosis and with a potentially progressive disease process. Consequently, we understand AF-and other arrhythmias such as re-entrant atrial tachycardia and sinus node disease-as a manifestation of the pre-existing FACM (13, 14) . This concept can explain the different clinical manifestations of AF, e.g., the appearance of relatively short episodes of paroxysmal AF over decades or "forever" in mild forms of FACM with a limited and stable fibrotic substrate, but also the appearance of "early persis- 
